What Ascarol Treats: Main Uses and Benefits

Ascarol is a supportive therapy used in situations involving certain distressing symptoms. This class of medication is applied across domains where additional symptomatic support is needed, generally addressing situations where symptoms create noticeable physiological strain.

Addressing Episodic Symptom Discomfort

Ascarol is considered relevant in clinical settings marked by increased discomfort or tension and conditions involving episodic or fluctuating manifestations. It is used for managing symptom clusters that may become intense or disruptive, such as those related to physical discomfort and systemic imbalance. This medication is often used when symptoms intensify and short-term symptomatic assistance is needed, contributing to easing the overall symptom load.

“This approach helps maintain a sense of stability when symptoms become more noticeable.”

Support for Functional Stability

Applied across domains where additional symptomatic support is needed, Ascarol provides support that helps ease the overall symptom burden. It is relevant for managing symptoms that interfere with daily comfort and is applicable when conditions present with disruptive symptom manifestations. Ascarol is relevant in contexts involving heightened systemic burden and is applied in situations involving certain distressing symptoms, assisting with maintaining functional stability when symptoms create noticeable functional strain.

Quick Fact: Relief for Discomfort
Ascarol is considered relevant when symptoms intensify, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus overview on Mesalamine

Regulatory information defines who is eligible for treatment with this medication and outlines specific patient populations for whom use is prohibited or requires careful medical assessment.

Populations for Whom Use is Contraindicated

Use is strictly prohibited in patients who have a known or suspected hypersensitivity to the active drug substance (mesalamine/aminosalicylates), to salicylates (including aspirin), or to any other ingredient in the product formulation. This is a primary, formal contraindication.

Populations Requiring Special Consideration

Certain pre-existing medical conditions necessitate caution and close monitoring during therapy:

• Renal Impairment: Patients with pre-existing kidney dysfunction, a history of renal disease, or those taking other drugs that may be harmful to the kidneys require initial and periodic evaluation of kidney function while on treatment.
• Hepatic Impairment: Individuals with known liver disease should be assessed for the risks and benefits of using the medicine, as cases of liver failure have been reported.
• Gastrointestinal Tract Obstruction: Caution is required in patients with conditions such as pyloric stenosis, as this may affect the drug's delivery and release characteristics in the colon.

Age and Physiological Eligibility

Age-related eligibility varies by formulation; one common formulation is approved for use in adults and pediatric patients aged 5 to 17 years. Limited data suggest its use in pregnancy is generally categorized as a low risk, but the benefit of therapy must always be weighed against potential risks to the fetus. The drug is considered a Category B in one older classification system.

Interactions with other Medicines and Products

This section details interaction patterns for Ascarol (Albendazole) as documented in official government regulatory information.

Interaction Classification and Constraints

The medicine's interaction profile is strongly influenced by its dependence on hepatic metabolism, which affects the plasma concentrations of the active metabolite, albendazole sulfoxide. Administration constraints require the tablet to be taken with a fatty meal to ensure the necessary increase in systemic exposure.

Interaction Type	Interacting Substance	Official Regulatory Outcome
Exposure-Increasing	Dexamethasone, Praziquantel, Cimetidine, Grapefruit Juice	Increases plasma concentrations and systemic exposure of albendazole sulfoxide.
Exposure-Decreasing	Phenytoin, Carbamazepine, Rifampicine, Ritonavir	May reduce plasma concentrations of the active metabolite, risking decreased effectiveness.
Pharmacodynamic Risk	Myelosuppressive agents	Co-administration may result in additive myelosuppression (bone marrow suppression).

Population-Specific Notes

Patients with liver disease (hepatic impairment) are noted in regulatory documents to be at increased risk for bone marrow suppression when Ascarol is co-administered with other myelosuppressive agents. Additionally, extrahepatic obstruction has been officially associated with a substantial increase in the systemic availability of albendazole sulfoxide.

How Ascarol Works

The action of Ascarol (Albendazole) is based on a selective mechanism that disrupts structural and metabolic elements of the parasitic organism. The drug is classified as a microtubule-destabilizing agent, and its mechanism operates across two key domains within the parasite.

---

Targeting Parasitic Microtubules

The active metabolite binds with affinity to the parasite's beta-tubulin subunit, preventing the necessary process of polymerization into microtubules. This structural failure initiates degenerative changes in the parasite's tegumental and intestinal cells.

---

Blocking Energy Pathways and Causing Starvation

The resulting loss of cytoplasmic microtubules compromises the parasite's ability to absorb glucose and essential nutrients from the host. This interference with the glucose uptake pathway leads to a rapid collapse of cellular energy metabolism, causing the depletion of ATP and stored glycogen. This systemic energy failure leads to the cessation of physiological activity and structural integrity loss in the parasitic organism.

How Ascarol is Used: Official Administration Guidelines

Ascarol (Albendazole) is strictly administered via the oral route and is available as a tablet or an oral suspension. The specific dosing schedule and duration are highly dependent on the type of parasitic infection being addressed, reflecting short-term or long-term administration patterns.

Dosing and Frequency For systemic infections, such as neurocysticercosis or hydatid disease, the medicine is typically prescribed at a dose of 400 mg twice daily for patients weighing 60 kg or more. Patients weighing less than 60 kg receive a weight-based dose of 15 mg/kg/day, divided into two daily administrations, with a maximum daily dose of 800 mg. In contrast, many common intestinal infections require a simpler single 400 mg dose.

Administration Context The medicine must be taken with food, ideally a fatty meal, as this significantly increases the drug's absorption into the body. For patients who cannot swallow the tablet whole, the official instructions permit the tablet to be crushed or chewed and then swallowed with water.

Duration and Population Use Treatment for systemic infections is often prolonged and follows a cyclic pattern; for instance, hydatid disease requires 28 days of dosing followed by a 14-day drug-free interval. Dosage adjustments are not expected for patients with renal impairment, but caution and evaluation are required for those with hepatic impairment due to increased drug exposure.

Research Evidence / Overview of Studies

Evaluation in Osteoarthritis (OA)

Research explored the effects on joint function and discomfort measures in patients with osteoarthritis (OA). The primary studies reviewed focused on the investigation of the compound’s effects on pain and mobility measures.

• Phase III Randomized Controlled Trial (RCT) One Phase III randomized controlled trial (RCT) reported lower pain scores after 12 weeks of administration, compared to baseline, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). In this study, the pain scores observed in the active group were lower than those observed in the placebo group.
• Mobility Outcomes Secondary outcomes from the RCT and supporting Phase II trials examined changes in patient-reported mobility, as measured by the 6-Minute Walk Test (6MWT). Findings were mixed; some studies reported no significant change in distance walked compared to placebo, while others reported a change.
• Inflammatory Markers A number of in vitro and small-scale human studies examined the compound's effect on inflammatory biomarkers. The observed change in inflammatory markers (CRP and IL-6) was noted in the study.

---

Other Conditions Investigated

Early studies also evaluated the compound’s role in managing pain and inflammation associated with rheumatoid arthritis (RA); however, the evidence is not yet conclusive. The clinical studies reviewed primarily focused on osteoarthritis. No other conditions were formally investigated in the included studies.

---

Safety and Tolerability Profile

Multiple studies have assessed the compound's safety profile, primarily in patients with osteoarthritis.

• Short-Term Safety The research reported common adverse events, which included gastrointestinal upset and headache. The frequency of these events was similar to that observed in the placebo group.
• Long-Term Safety Another study focused on long-term safety. The study reported no significant increase in adverse events compared to placebo over one year in the tested population. The study identified no new safety concerns during the 12-month follow-up.

The available studies provide information on the compound’s role, but it is important to consult a healthcare provider for personalized medical advice.

Common questions about Ascarol (FAQ)

Q: Is it normal to feel tired or dizzy after starting Ascarol?

Official information lists dizziness (vertigo) as an adverse reaction that can occur when taking Ascarol. General tiredness, or asthenia, has also been noted in post-marketing reports for the drug. If dizziness or excessive tiredness is experienced, a healthcare professional should be consulted.

Q: Can I drink alcohol while I am taking Ascarol?

It is generally advised to avoid drinking alcohol while taking this medication. Both alcohol and Ascarol can affect the liver, and combining them may increase the risk of liver damage. Any use of alcohol should be discussed with a healthcare provider.

Q: Is Ascarol safe for use in older adults (seniors)?

Regulatory data on the safety and effectiveness of Ascarol specifically in patients aged 65 and older is limited for certain conditions. While some studies have included seniors, there is not enough data to determine if their response is different from that of younger patients. Use in older adults requires individual risk-benefit assessment by a healthcare provider.

Q: Can children or teenagers take Ascarol?

Yes, Ascarol is approved for use in certain pediatric patients. The specific amount used is based on the child's weight and the infection being treated. Official guidance notes that the drug is not recommended for some uses in children under two years of age.

Q: What happens if I miss a dose of Ascarol?

Official advice states that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for your next scheduled dose, it is advised to skip the missed dose and resume the regular dosing schedule. Official guidance advises against taking a double dose to make up for a missed one.

Q: Are there any long-term side effects associated with Ascarol use?

Severe adverse reactions, including aplastic anemia (a serious blood disorder) and severe hepatotoxicity (liver damage), have been reported. Due to these risks, prolonged, high-dose treatments for systemic infections require regular blood tests to monitor blood cell counts and liver enzyme levels.

Q: Does Ascarol affect blood pressure or heart rate?

Specific changes to blood pressure or heart rate are not commonly listed among the adverse events in regulatory documents. Rare adverse effects, such as chest pain, have been noted.

Q: Does Ascarol have a generic version available?

Yes, Ascarol is the trade name for the active ingredient albendazole. Albendazole is available as a generic medication, which may be a lower-cost option compared to the brand-name product.

Q: Is Ascarol used for chronic or short-term conditions?

Ascarol can be used for both. Some simpler parasitic infections may require only a single dose (short-term), while more serious systemic infections may require therapy lasting for multiple cycles over several months or years.

Q: What foods or supplements should I avoid when using Ascarol?

Regulatory information indicates that grapefruit juice should be avoided as it may increase the levels of the active drug in the body. The medication itself must be taken with food, ideally a fatty meal, to ensure proper absorption and effectiveness.

Q: Does Ascarol interact with birth control pills?

While specific interactions with oral contraceptives are not listed, the official label strongly advises that females of reproductive potential use an effective method of non-hormonal contraception during treatment and for three days after the final dose. This recommendation is based on the documented risk of harm to a developing fetus.

Q: Are there specific storage instructions for Ascarol (e.g., must it be refrigerated)?

No, Ascarol should not be refrigerated. It must be stored at typical room temperature, away from excess heat and moisture. To maintain its stability, the tablets must be kept in their original container and protected from light.

Q: What does it mean if Ascarol causes a mild rash?

Skin rash and itching (pruritus) are listed as uncommon side effects. A rash can be a sign of a more severe reaction. Consult a healthcare provider if a rash occurs.

Q: Can people with liver or kidney issues use Ascarol?

Patients with pre-existing liver disease require careful assessment and increased monitoring of blood cell counts and liver enzymes due to an elevated risk of severe adverse effects. The medication is negligibly eliminated by the kidneys, so changes to the amount used are not typically required for pre-existing kidney issues.

Q: Is it true that Ascarol can cause dry mouth?

Dry mouth is not listed as a common or serious adverse reaction in the official regulatory documentation for Ascarol.

Q: How long does a course of Ascarol treatment usually last?

The length of treatment varies significantly. For example, some intestinal infections may require just a single dose, while serious systemic infections may be treated with cycles of medication (such as 28 days on, 14 days off) that can be repeated over an extended period.

Q: Does Ascarol make you sensitive to the sun?

Photosensitivity, or an increased sensitivity to the sun, is not explicitly listed as a common or serious side effect in the regulatory documents for this drug.

Q: Are there any known withdrawal effects when stopping Ascarol?

Withdrawal symptoms are not listed as an expected side effect when stopping Ascarol. Treatment is typically discontinued once the infection is cleared or if a patient experiences significant adverse effects, such as low blood cell counts or liver abnormalities.

Q: Can Ascarol be crushed or split if a tablet is difficult to swallow?

Official instructions confirm that Ascarol tablets may be either crushed or chewed and then swallowed with a drink of water. This is an allowed administration method for patients who have trouble swallowing the tablet whole.

Q: Is Ascarol considered a high-risk medication during pregnancy?

Yes, Ascarol is considered a high-risk medication during pregnancy. Based on studies in animals, the drug may cause harm to the fetus. It is recommended for use only when there are no alternative treatments and the potential benefit to the mother is determined to outweigh the potential risk to the fetus.

Q: Can Ascarol be used by people who are breastfeeding?

Studies suggest that Albendazole and its active form are minimally excreted into breastmilk. An expert group to the World Health Organization concluded that a single oral dose may be given to lactating women.

Q: Can Ascarol cause confusion or changes in mood?

Confusion is listed as an uncommon adverse reaction in the official drug information. However, general changes in mood are not explicitly listed among the reported side effects for Ascarol.

Q: How long after taking Ascarol should I wait before driving or operating machinery?

Due to the risk of side effects like dizziness or vertigo, Ascarol can temporarily affect a person's alertness and coordination. It is advised not to drive or operate complex machinery until an individual is certain how the medication affects them.

Q: Are there different strengths of Ascarol, and how are they prescribed?

Ascarol (Albendazole) is typically supplied as a 200 mg oral tablet. While the tablet strength is fixed, the total dose taken is based on the type of infection and, for certain systemic diseases, the patient's body weight. This may require taking two tablets per dose.

Q: What should I do if the side effects of Ascarol are bothersome but not severe?

Official labels recommend continuing treatment for the full prescribed duration. However, a healthcare professional should be contacted if side effects are bothersome or concerning.

Q: Is Ascarol available in different forms (e.g., tablet, liquid, injection)?

Ascarol is primarily available as an oral tablet, which may include a chewable form. It can also be supplied as an oral suspension (liquid form) for certain populations, but it is not typically available as an injection for general use.

Q: What is the difference in effect between taking Ascarol with food versus without food?

For Ascarol to work effectively against systemic infections, it must be absorbed well by the body. Taking it with a meal, especially one that contains some fat, significantly increases the amount of drug absorbed. Therefore, it is advised that the medication always be taken with food.

Q: How soon after stopping Ascarol can I safely take an interacting medicine?

While specific guidance for drug-drug interactions must be requested from a doctor, official advice for females of reproductive potential suggests a clearance time. An effective method of contraception is required for three days after the final dose to avoid the risk of fetal harm, which indicates the drug is cleared from the system within that window.

How to Store and Dispose of Ascarol (Albendazole) Tablets

The storage and disposal of Ascarol (Albendazole) must strictly follow conditions defined in the official regulatory labeling to maintain product stability.

Storage Requirements

Ascarol tablets must be stored at room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from light and kept away from excess heat and moisture in a tightly closed container. It is critical to keep the tablets in the original container and out of the sight and reach of children.

Disposal

Expired or unused tablets must be disposed of in accordance with local requirements. Official regulatory guidance advises against discarding medicines via wastewater or household trash.